Nicotine increases serotonin release in the brain and symptoms of nicotine withdrawal may be modulated by diminished serotonergic neurotransmission. The promoter region of the serotonin transporter gene, solute carrier family neurotransmitter transporter member 4 (SLC6A4), contains a functional tandem repeat polymorphism. The long (L) variant is more actively transcribed than the short (S) variant and is associated with a higher serotonin uptake. To investigate the potential role of this polymorphism for smoking behavior, SLC6A4 genotypes were determined in two different studies, the SMOKING GENES case-control study (470 current smokers and 419 subjects who had never smoked) and the cross-sectional Ludwigshafen risk and cardiovascular health (LURIC) study (777 current smokers and 1178 subjects who had never smoked). In the SMOKING GENES case-control study, SLC6A4 genotype frequencies were not statistically different between smokers (LL: 30.9%; LS: 46.8%; SS: 16.4%) and non-smokers (LL: 36.3%; LS: 41.8%; SS: 14.3%; P ¼ 0.13). Similar results were obtained in the crosssectional LURIC study (smokers: LL, 36.5%, LS, 45.6%, SS, 17.9%; nonsmokers: LL, 33.6%, LS, 48.9%, SS, 17.6%; P ¼ 0.33). SLC6A4 genotypes were furthermore not associated with Fagerstrom Tolerance Questionnaire score, packyears, number of cigarettes smoked per day or previous attempts to quit smoking. We conclude that the SLC6A4 promoter polymorphism is not a major determinant of smoking behavior in Caucasian.
Introduction
Tobacco consume is the most important preventable cause of mortality and morbidity in Western societies. Overall death rate is twice as high in nicotine smokers than in non-smokers. 1 Smoking behavior is influenced by both genetic and environmental factors. 2, 3 Twin studies strongly support the notion that genetic factors are involved in the initiation, continuation and cessation of smoking. 4 Inheritability rates have been estimated to be about 50% for initiation and 60% for persistence of smoking. 5 The serotoninergic system is known to modulate mood, emotion, sleep and appetite and is implicated in the control of numerous behavioral and physiological functions. 6 The serotonin transporter in the brain and in many peripheral tissues is responsible for the active transport of serotonin into neurons, enterochromaffine cells, platelets and other cells. 7 The gene coding for this transporter, solute carrier family neurotransmitter transporter member 4 (SLC6A4), maps to chromosome 17q11.1-q12 8 and encodes a protein of 630 amino acids. 6 The SLC6A4 promoter region contains a polymorphic region with 16 (long variant, L) or 14 (short variant, S) repeats of a 22 bp element. The L variant is more actively transcribed than the S variant and is associated with a higher serotonin uptake. 9, 10 Some studies have associated this polymorphism with anxiety-related and harm-avoiding personality traits, 8, 11, 12 but this was not confirmed in others. 13, 14 It has been suggested that such personality traits are, among others, typical predictors of smoking behavior. 15 The role of the SLC6A4 polymorphism for smoking is currently under debate. In two previous studies, the SLC6A4 L variant was found more often among smokers. 16, 17 In contrast to that, Gerra et al. 18 reported an over-representation of the S variant among smokers and one study found no association between SLC6A4 genotypes and smoking. 19 To address the role of the SLC6A4 promoter polymorphism for smoking behavior, we evaluated probands from two separate studies, the SMOKING GENES case-control study and the cross-sectional Ludwigshafen Risk and Cardiovascular Health (LURIC) cohort.
Results
In the SMOKING GENES case-control study, SLC6A4 genotypes were successfully determined in 440 (94%) smokers and 387 (92%) non-smoking control subjects. Genotype frequencies did not deviate from the HardyWeinberg equilibrium and were not significantly different between smokers and non-smokers (Table 1) . SLC6A4 genotypes were furthermore not associated with Fagerstrom Tolerance Questionnaire score, number of cigarettes smoked per day, packyears or previous attempts to quit smoking (Table 2 ).
In the cross-sectional LURIC study, self-reported smoking behavior was verified by the determination of plasma cotinine levels. Subjects with cotinine levels 415 mg/l were considered as current smokers. Self-reported smoking behavior and cotinine levels were contradictory in a total of 113 (3.4%) study participants (16 self-reported never-smokers and 107 self-reported ex-smokers).
SLC6A4 genotype frequencies were successfully determined in 770 (99.1%) smokers and 1168 (99.2%) nonsmokers and did not deviate from the Hardy-Weinberg equilibrium. No association was found between SLC6A4 genotypes and smoking habit (Table 3 ). Among smokers of the LURIC study, SLC6A4 genotypes were also not associated with cumulative (LL: 32722; LS: 34723; SS: 33723 packyears; P ¼ 0.44) or current (LL: 21713; LS: 21713, SS: 21713 cigarettes per day; P ¼ 0.71) nicotine consumption. 
Serotonin transporter gene polymorphism and smoking

O Trummer et al
Discussion
We have tested the potential influence of a functional polymorphism in the serotonin transporter gene SLC6A4 with smoking behavior in two different settings, the SMOKING GENES case-control study and the cross-sectional LURIC study. In both studies, SLC6A4 genotypes were not associated with smoking habit. Combining participants from SMOKING GENES and LURIC, the present study had a statistical power of 0.89 and 0.97 to detect odds ratios of 1.4 and 1.5, respectively, in carriers of an SS genotype. Our negative findings are in line with a previous study from Lerman et al. 19 Two other studies reported an association of the SLC6A4 L variant with smoking, 16, 17 whereas one study linked the S variant to smoking. 18 The reason for these conflicting data is unclear and may be explained by different genetic background and different social and environmental influences on smoking behavior.
Furthermore, researchers should be aware of the high risk of false-positive findings in genetic association studies. 20 The confidence to genetic association studies has been undermined by a variety of publications showing positive results, which were later followed and refuted by contradictory studies. 21, 22 Our results clearly suggest that the SLC6A4 promoter tandem repeat polymorphism is not associated with smoking behavior. We have not measured serotonin levels and are therefore unable to draw firm conclusions on the potential role of serotonin itself for smoking habits. Furthermore, we cannot exclude that other polymorphisms in the SLC6A4 gene, such as the variable number of tandem repeats (VNTR) polymorphism in intron 2, 23 may be associated with smoking behavior.
A clear genetic influence on smoking behavior has been shown by twin studies. 3, 4 Beside the serotonin transporter gene, SLC6A4, several other genes such as the nicotinemetabolizing cytochrome P450 2A6, dopamine receptors (DRD1-5) and transporters (SLC6A3), tyrosine hydroxylase or tryptophan hydroxylase may be regarded as promising candidates for genetic association studies.
Materials and methods
SMOKING GENES study
Between May 2003 and September 2005, 470 healthy current smokers were recruited. All study participants completed a questionnaire regarding personal traits and current smoking habits as well as the Fagerstrom Questionnaire for estimation of nicotine-dependancy. 24 The control group consisted of 419 subjects who had never smoked. The study was conducted according to the Austrian Gene Technology Act and approved by the local ethics committee. All subjects were Caucasians of middle-European (Austrian) origin. All subjects gave their written informed consent before entering the study.
LURIC study
The LURIC study includes consecutive Caucasian patients hospitalized for coronary angiography between June 1997 and May 2001. The study was approved by the ethics review committee at the 'Landesärztekammer Rheinland-Pfalz' (Mainz, Germany) and written informed consent was obtained from the participants. A detailed description of the LURIC study design and baseline characteristics has been published. 25 Data on smoking habits were retrieved using questionnaires. Additionally, to detect 'hidden' smokers, plasma cotinine levels were determined using a commercial Radio Immuno Assay (cotinine RIA; DPC Biermann, Germany). In the present study, from a total of 3316 LURIC participants, only current smokers (n ¼ 777) and subjects who had never smoked (n ¼ 1178) were used for further analysis.
Genomic DNA was isolated from peripheral whole bloodcells by a silica-membrane spin column method according to the manufacturer's instructions (GenElute, Sigma, Vienna, Austria). Genotyping of the SLC6A4 promoter polymorphism was performed by size analysis of polymerase chain reaction products. Briefly, the polymorphic region was amplified using 5 0 -CTAACCCCTAATGTCCCTACTGCAGCC-3 0 as forward primer and 5 0 -GTGCAGGGGGATGCTGGAA-3 0 as reverse primer. Amplified products had a size of 222 (L allele) or 179 bp (S allele) and were analyzed by agarose gel electrophoresis.
Statistical analysis was carried out using SPSS 11.0 for Windows. Normal distribution of data was analyzed with the Kolmogorov-Smirnov test. Numeric values were analyzed by Student's t-test, and data showing unequal variance or departing from the normal distribution were analyzed by Mann-Whitney rank-sum test. Categorial variables were compared by the w 2 test. The criterion for statistical significance was Po0.05.
Abbreviations
DRD
dopamine receptor L long LURIC Ludwigshafen Risk and Cardiovascular Health S short SLC6A3 solute carrier family neurotransmitter transporter member 3 SLC6A4 solute carrier family neurotransmitter transporter member 4
